Fig. 2From: Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority studyHealing rate of erosive esophagitis at week 4 and up to week 8 according to the Los Angeles Classification (per protocol set)Back to article page